ASCO GU 2024: Adjuvant Pembrolizumab Improves Survival in Patients With Kidney Cancer
Survival benefit seen across a variety of patient subgroups
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Survival benefit seen across a variety of patient subgroups
Only registered members have full access to PracticeUpdate content.